


We encourage you to use these slides when teaching. If you do, please cite this source and note any changes made.

- The Immersion Training in Addiction Medicine Program

Brief Intervention Efficacy

Richard Saitz MD, MPH, FACP, DFASAM

Chair, Department of Community Health Sciences
Professor of Community Health Sciences & Medicine



Boston Medical Center is the primary teaching affiliate
of the Boston University School of Medicine.



What is Brief Intervention?

- 10-15", empathic, non-confrontational
- Feedback
 - Ask permission
 - Ask what patient thinks of it
- Advice (clear)
- Goal setting
 - Negotiate
 - Menu of options
 - Support self-efficacy
- Follow-up



“You are drinking more than is safe for your health.”

“My best medical advice is that you cut down or quit.”


“What do you think? Are you willing to consider making changes?”

How to Advise or Refer Patients	Examples or Explanations
Elicit information about how the patient views the problem.	“What do you think about your drinking? Are you ready to make a change in your alcohol use? How confident are you that you could cut down if you wanted to?”
Express concern and provide clear advice regarding the ideal goal (abstinence or reduced consumption for those with nondependent alcohol use, achieved through brief counseling; abstinence for patients with alcohol dependence). ^b	“I am concerned about your drinking; my medical advice is that the healthiest choice for you is to cut down or abstain.”
Provide specific feedback about alcohol consumption in comparison with population norms, and link existing problems to alcohol use when appropriate, to make information relevant to the patient.	“Ninety-three percent of adults drink less than the amounts you report drinking. You mentioned your heartburn is worse when you drink. Alcohol is probably causing your heartburn.”
Express empathy, let the patient know you believe that change is possible, and acknowledge that it is the patient’s responsibility to change.	“The fact you were able to quit before for a week tells me you can do it again. But it must be difficult. It is up to you to make these changes.”
When the patient expresses interest or gives permission, provide information, including a menu of options, about how to change.	“Would you like information on how to cut down or abstain? Other people have found a range of options helpful, such as keeping a drinking diary, counseling, and mutual-help groups. What do you think about these?”
Anticipate and discuss situations in which the patient feels at risk for drinking excessively, and talk about strategies to avoid drinking excessively.	“What ways might help you avoid drinking excessively when you go out with friends who drink?” Have the patient keep a drinking diary (including the number of drinks consumed per day).





EFFICACY



**RANDOMIZED TRIALS OF
SCREENING AND BRIEF INTERVENTION VS.
NO SCREENING**

NONE

EFFICACY OF ALCOHOL BI VS. NO BI

- Efficacious: **10-15" multi-contact**
 - ≥ 23 original RCTs,* 9 systematic reviews, **primary care, non-dep, screen id'd**
 - **Lower proportion of drinkers self-reporting risky amounts**
 - 57% vs. 69% at 1 year (n=2784)**; 11% risk diff (n=5973)*
 - **Lower self-reported consumption (n=5639)**
 - by 15% (38 grams per week)(n=5639)***; 3.6 drinks/wk (n=4332)*
 - Accidents, injuries, liver problems, hospital/ER/primary care use, legal problems, quality of life: **insufficient evidence***
 - Decreased hospital utilization (≥ 2 RCTs)
 - Cost-effective (spend \$166, save \$546 medical, \$7780 society)
 - Decreased mortality (RR 0.47)(4 RCTs (n=1640))
 - Prevention of disorder – no evidence

*Jonas DE et al. *Ann Intern Med* 2012;157:645-54.

Kaner et al. *Drug and Alcohol Review* 2009;28:301-23


**Beich et al. *BMJ* 2003;327:536

***Bertholet et al. *Arch Intern Med.* 2005;165:986

Kristenson H, et al. *Alcohol Clin Exp Res* 1983;7:203 (mortality, 3-16 yrs)

Fleming MF et al. *Alcohol Clin Exp Res.* 2002;26(1):36-43 (cost)

Cuijpers et al. *Addiction* 2004;99: 839-845 (mortality)



SETTING


- Evidence is mixed for emergency and hospital
- Most people identified by screening in hospitals have a mod/severe disorder
- Different expectations and goals
 - Comprehensive care?
 - Preventive care?
 - Longitudinal care? Long-term therapeutic alliance?
 - Teachable vs. learnable moments?



Belen Martinez et al INEBRIA 2007
Saitz et al. Ann Intern Med 2007;146:167-76
Freyer-Adam J et al. Drug Alcohol Depend 2008
Bischoff G et al. Drug Alcohol Depend 2008
Bischof et al. Int J Pub Health 2010
Saitz et al. Int J Pub Health 2010



McQueen J. Cochrane review 2011
D'Onofrio RCTs; Schmidt CS. Et al. Addiction, 2016;111: 783–794
Very small effect (meta-analysis).
Gentilello et al 1999 and subsequent studies



SBI FOR DRUGS IN ADULTS

Study	Result	Setting
Bernstein 2005	5-9% incr coc/her abst	
Zahradnik, Otto	Less addictive rx use	
WHO (Humeniuk)	7% diff in score /	
Woodruff		
Saitz		
Blumenthal		
Field		

Editorials represent the opinions of the authors and JAMA and not those of the American Medical Association.


Opinion

EDITORIAL

Screening and Brief Intervention and Referral to Treatment for Drug Use in Primary Care Back to the Drawing Board

Ralph Hingson, ScD, MPH; Wilson M. Compton, MD, MPE

n=334 ASSIST 4-26; 78% F/U; Combined, repeated; some urine tests
ED; 81% F/U; urine testing
Large trauma bio testing



YOUTH DRUG SBI RCTS: PROMISING


- ① n=59 **adolescents in primary care** in Brazil-decreased MJ and stimulant use and problems
- ② Decreased marijuana use by **adolescents in the emergency department** in a pilot study (n=210)
- ③ Decreased cannabis problems and drug use (computer BI) and cannabis DUI (therapist) by **adolescents in primary care** (n=328)
- ④ Computer (but not therapist) BI *prevented* cannabis (17% vs 24%, 1 yr) use in adolescents in primary care (n=714)

DeMicheli D et al. Rev Assoc Med Bras 2004; 50(3): 305-13

Bernstein E et al. Acad Emerg Med 2009; 16: 1174-85

Walton MA (Blow) et al. Drug Alcohol Dependence 2013;132:646-53.

Walton MA (Blow) et al. Addiction 2013;109:786-97.



Original Investigation
Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence: A Randomized Clinical Trial

Gail D’Onofrio, MD, MS; Patrick G. O’Connor, MD, MPH; Michael V. Fenton, PhD; Marek C. Chawarski, PhD; Susan H. Bush, PhD; Patricia H. Owens, MS; Steven L. Bernstein, MD; David A. Fiellin, MD

IMPORTANCE: Opioid-dependent patients often use the emergency department (ED) for medical care.

OBJECTIVE: To test the efficacy of 3 interventions for opioid dependence: (1) screening and referral to treatment (referral); (2) screening, brief intervention, and facilitated referral to community-based treatment services (brief intervention); and (3) screening, brief intervention, ED-initiated treatment with buprenorphine/naloxone, and referral to primary care for 10-week follow-up (buprenorphine).

DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial involving 529 opioid-dependent patients who were treated at an urban teaching hospital ED from April 2, 2009, through June 26, 2013.

MAIN RESULTS AND MEASURES: Enrollment in and receiving addiction treatment 30 days after randomization was the primary outcome. Self-reported days of illicit opioid use, urine testing for illicit opioids, human immunodeficiency virus (HIV) risk, and use of addiction treatment services were the secondary outcomes.

RESULTS: Seventy-eight percent of patients in the buprenorphine group (89 of 114) and 30% of patients in the referral group (30 of 100) were enrolled in addiction treatment 30 days after randomization ($P < .001$). The buprenorphine group reduced the number of days of illicit opioid use from 5.8 days (95% CI, 5.1–6.5) to 0.9 days (95% CI, 0.5–1.3) ($P < .001$) for both treated and untreated patients ($P < .001$ for the interaction effect). The rates of urine samples not tested negative for opioids did not differ statistically across groups, with 10% of patients in the buprenorphine group (9 of 91) and 11% of patients in the referral group (11 of 100) using inpatient addiction treatment services. There were no statistically significant differences in HIV risk across groups ($P = .66$). Eleven percent of patients in the buprenorphine group (12 of 114) used inpatient addiction treatment services.

CONCLUSIONS AND RELEVANCE: Among opioid-dependent patients, ED-initiated buprenorphine treatment vs brief intervention and referral significantly increased enrollment in addiction treatment, reduced self-reported illicit opioid use, and decreased use of inpatient addiction treatment services but did not significantly decrease the rates of urine samples that tested positive for opioids or of HIV risk. These findings require replication in other centers.

KEY WORDS: buprenorphine, emergency department, opioid dependence, randomized clinical trial, screening, brief intervention, facilitated referral, addiction treatment, urine testing, HIV risk, inpatient addiction treatment services.

INTRODUCTION: Opioid dependence is a leading cause of death in the United States, with an estimated 16,000 deaths in 2010.¹ The majority of these deaths are attributed to overdose, and many of these individuals are seeking medical attention in the emergency department (ED).² The ED is often the only point of contact for these patients, and it is an ideal setting for identifying and treating opioid dependence.

Screening and referral to treatment (referral) is a common approach to identifying and treating opioid dependence in the ED. However, referral alone is often insufficient to ensure that patients receive the treatment they need. Brief intervention and facilitated referral to community-based treatment services (brief intervention) is a more comprehensive approach that includes a brief assessment of the patient’s needs and a referral to a community-based treatment program.

ED-initiated treatment with buprenorphine/naloxone (buprenorphine) is a more intensive approach that includes a brief assessment of the patient’s needs, a referral to a community-based treatment program, and the initiation of buprenorphine/naloxone treatment in the ED. This approach has been shown to be effective in increasing enrollment in addiction treatment and reducing self-reported illicit opioid use.

This randomized clinical trial compared the efficacy of these 3 interventions for opioid dependence in an urban teaching hospital ED. The primary outcome was enrollment in addiction treatment 30 days after randomization. Secondary outcomes included self-reported days of illicit opioid use, urine testing for illicit opioids, HIV risk, and use of inpatient addiction treatment services.

The results of this trial show that ED-initiated buprenorphine treatment significantly increased enrollment in addiction treatment and reduced self-reported illicit opioid use compared with referral and brief intervention. These findings suggest that ED-initiated buprenorphine treatment may be a more effective approach to identifying and treating opioid dependence in the ED.

These findings have important implications for the management of opioid dependence in the ED. ED-initiated buprenorphine treatment may be a more effective approach to identifying and treating opioid dependence in the ED, and it may be worth considering as a standard of care for these patients.

Further research is needed to evaluate the long-term efficacy and safety of ED-initiated buprenorphine treatment. In particular, it is important to evaluate the impact of this approach on patient outcomes, such as enrollment in addiction treatment, self-reported illicit opioid use, and HIV risk.

In conclusion, ED-initiated buprenorphine treatment is a more effective approach to identifying and treating opioid dependence in the ED compared with referral and brief intervention. These findings suggest that ED-initiated buprenorphine treatment may be a more effective approach to identifying and treating opioid dependence in the ED.

These findings have important implications for the management of opioid dependence in the ED. ED-initiated buprenorphine treatment may be a more effective approach to identifying and treating opioid dependence in the ED, and it may be worth considering as a standard of care for these patients.

Further research is needed to evaluate the long-term efficacy and safety of ED-initiated buprenorphine treatment. In particular, it is important to evaluate the impact of this approach on patient outcomes, such as enrollment in addiction treatment, self-reported illicit opioid use, and HIV risk.

In conclusion, ED-initiated buprenorphine treatment is a more effective approach to identifying and treating opioid dependence in the ED compared with referral and brief intervention. These findings suggest that ED-initiated buprenorphine treatment may be a more effective approach to identifying and treating opioid dependence in the ED.

These findings have important implications for the management of opioid dependence in the ED. ED-initiated buprenorphine treatment may be a more effective approach to identifying and treating opioid dependence in the ED, and it may be worth considering as a standard of care for these patients.

Further research is needed to evaluate the long-term efficacy and safety of ED-initiated buprenorphine treatment. In particular, it is important to evaluate the impact of this approach on patient outcomes, such as enrollment in addiction treatment, self-reported illicit opioid use, and HIV risk.

In conclusion, ED-initiated buprenorphine treatment is a more effective approach to identifying and treating opioid dependence in the ED compared with referral and brief intervention. These findings suggest that ED-initiated buprenorphine treatment may be a more effective approach to identifying and treating opioid dependence in the ED.

JAMA Report Video and Author Video Interview at jama.com

CME Quiz at jamanetwork.com and CME Questions page 1670

Author affiliations: Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut (D’Onofrio, Fenton, Bernstein, Owens, Bush, Fiellin); Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut (Chawarski); Yale School of Public Health, New Haven, Connecticut (Bush, Fiellin); Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut (O’Connor); Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut (Bernstein); Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut (Owens); Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut (Fiellin).

Address correspondence and reprint requests to Dr D’Onofrio at the Department of Emergency Medicine, Yale School of Medicine, 333 Cedar St, Box 3333, New Haven, CT 06510 (e-mail: gail.donofrio@yale.edu).

© 2015 American Medical Association. All rights reserved. This article is intended solely for the individual user and cannot be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage and retrieval system, without permission in writing from the American Medical Association.

DOI: 10.1001/jama.2015.3498

Published online July 14, 2015.

Address correspondence and reprint requests to Dr D’Onofrio at the Department of Emergency Medicine, Yale School of Medicine, 333 Cedar St, Box 3333, New Haven, CT 06510 (e-mail: gail.donofrio@yale.edu).

© 2015 American Medical Association. All rights reserved. This article is intended solely for the individual user and cannot be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage and retrieval system, without permission in writing from the American Medical Association.

DOI: 10.1001/jama.2015.3498

Published online July 14, 2015.

Address correspondence and reprint requests to Dr D’Onofrio at the Department of Emergency Medicine, Yale School of Medicine, 333 Cedar St, Box 3333, New Haven, CT 06510 (e-mail: gail.donofrio@yale.edu).


© 2015 American Medical Association. All rights reserved. This article is intended solely for the individual user and cannot be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage and retrieval system, without permission in writing from the American Medical Association.

(screen), TREAT AND REFER (vs SBI vs S...RT)...

- ✓ increased engagement in addiction treatment (78% vs 41%),
 - ✓ reduced self-reported illicit opioid use (5 to 1 vs 2 days/wk)
 - ✓ decreased use of inpatient addiction treatment services
 - ✓ did *not* decrease the rates of urine samples positive for opioids
- *34% seeking treatment, 9% overdose, 73% past drug treatment

(*e.g. Terrific! Though not SBIRT)

D’Onofrio et al. JAMA 2015



SBI DRUGS

- Harder to change a behavior that is not socially sanctioned yet being done or that is not particularly problematic from the patient's perspective
- Injection, heroin, rx drugs cocaine, MJ, qualitatively different
- Other reasons to ask/intervene
 - interactions/safety, diagnoses, help-seeking/recognized
- Need better ways to address in general medical settings...repeated BI and/or just treat



What works?
Clinical effectiveness.

BMJ


BMJ 2013;346:e8501 doi: 10.1136/bmj.e8501 (Published 9 January 2013)

Page 1 of 14

RESEARCH

Effectiveness of screening and brief alcohol intervention in primary care (SIPS trial): pragmatic cluster randomised controlled trial

 OPEN ACCESS



Copyright 2008 John Crowther



"I've heard the saying, but I never thought it was something that could actually happen."

SUMMARY/IMPLICATIONS

- Brief intervention involves **feedback, advice and goal setting**
- Among those identified by screening, the best evidence for efficacy is for reducing self-reported alcohol consumption in primary care settings
 - Efficacy for disorders, drugs and in acute care settings limited
- Likely effective for health behaviors (e.g. drug use) among those seeking your help
- Feasible in general health settings
- Can be done by generalists
- Repeat or just treat

BEST ADVICE

- Abstinence
 - Failed attempts at cutting down
 - Dependence
 - Pregnancy/preconception
 - Contraindicated medical condition or medication
- Cutting down
 - Risky or problem use


“Beyond Screening”

- Determine the patient’s perception of his/her use, both the need and perceived ability to change behavior

Example: “Do you think your drug use is a problem?”

- Assess the patient’s stage of readiness to change behavior

Samet, JH, Rollnick S, Barnes H. *Arch Intern Med.* 1996;156:2287-2293.



FEEDBACK

Provide personalized feedback and state your concern.

- GGT
- drinking data
- risky behaviors
- consequences

ADVICE

Make explicit recommendation for change in behavior

- Emphasis on personal RESPONSIBILITY for change
 - “...it’s up to you to decide...”
- Give them a menu of options
- Use an EMPATHIC counseling style

GOAL SETTING

Discuss patient's reaction and negotiate plan.

- Enhancement of SELF-EFFICACY
- Reinforce it, state your belief they can do it
- Give example of patient's past success

Precontemplation

- Goal is to raise doubt, increase perception/ consciousness of problem
 - express concern
 - state the problem non-judgmentally
 - agree to disagree
 - advise a trial of abstinence or cutting down
 - importance of follow-up (even if using)
 - less intensity is better

Contemplation

- Goal is to tip the balance
 - elicit positive and negative aspects of drinking
 - elicit positive and negative aspects of not drinking
 - summarize (patient could write these down)
 - demonstrate discrepancies between values and actions
 - advise a trial of abstinence or cutting down

Determination

- Goal is to help determine the best course of action
 - working on motivation is not helpful
 - supporting self-efficacy is (remind of strengths-- i.e. period of sobriety, coming to doctor)
 - help decide on achievable goals
 - caution re: difficult road ahead
 - relapse won't disrupt relationship

Action

- Goal is to help patient take steps to change
 - support and encouragement
 - acknowledge discomfort (losses, withdrawal)
 - reinforce importance of recovery

Maintenance

- Goal is to help prevent relapse
 - anticipate difficult situations (triggers)
 - recognize the ongoing struggle
 - support the patient's resolve
 - reiterate that relapse won't disrupt your relationship

Relapse

- Goal is to renew the process of contemplation
 - explore what can be learned from the relapse
 - express concern
 - emphasize the positive aspects of prior abstinence and of current efforts to seek care
 - support self-efficacy

Brief Counseling Interventions: Summary

- Assess to determine best advice
- Assess readiness to change
- Counsel including known effective elements of brief intervention
 - Feedback, advice, goal setting